All In Biotech

Drug Trial Radar · NCT05844735

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

A Two-part, Randomized Partially-blinded, Parallelgroup, Placebo- and Active Comparatorcontrolled Phase 1 Study to Evaluate the Photosafety of Repeated Oral Dose of SAR441566 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

May 22, 2023

Primary completion

Oct 15, 2023

Study completion Oct 23, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center randomized parallel-group partially-blinded, 4-arm Phase 1 study to evaluate the phototoxic potential of two dose levels of SAR441566 treatment compared to placebo and the active comparator, ciprofloxacin, in healthy adults, 18 to 55 years of age. There will be two parts: * Part I is a randomized placebo-controlled trial comparing sensitivity to ultraviolet (UV) light in participants treated with SAR441566 to those treated with placebo. * Part II is an open label arm consisting of participants treated with ciprofloxacin which induces mild phototoxicity and serves as a positive control.

Conditions

  • Rheumatoid Arthritis

Interventions

  • SAR441566Drug

    Tablet

  • PlaceboDrug

    Tablet

  • CiprofloxacinDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 1Time frame: On-drug Day 8
  2. Treatment part I: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 1Time frame: On-drug Day 8
  3. Treatment part I: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 1Time frame: On-drug Day 9
  4. Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 2Time frame: On-drug Day 8
  5. Treatment part I: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 2Time frame: On-drug Day 8
  6. Treatment part I: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 2Time frame: On-drug Day 9

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TKL Research, Inc. Site Number : 8400001

    Fair Lawn, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.